Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: A multicenter phase 1/2 open-label study

Blood

Volumn 122, Issue 16, 2013, Pages 2799-2806

  Larocca, Alessandra ^a   Montefusco, Vittorio ^b   Bringhen, Sara ^a   Rossi, Davide ^c   Crippa, Claudia ^d   Mina, Roberto ^a   Galli, Monica ^e   Marcatti, Magda ^f   La Verde, Giacinto ^g   Giuliani, Nicola ^h   Magarotto, Valeria ^a   Guglielmelli, Tommasina ⁱ   Rota Scalabrini, Delia ^j   Omedé, Paola ^a   Santagostino, Alberto ^k   Baldi, Ileana ^l   Carella, Angelo Michele ^m   Boccadoro, Mario ^a   Corradini, Paolo ^b   Palumbo, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d SPEDALI CIVILI   (Italy)

^e PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h UNIVERSITY OF PARMA   (Italy)

ⁱ SAN LUIGI GONZAGA HOSPITAL   (Italy)

^j Ordine Mauriziano di Torino   (Italy)

^k SANT'ANDREA HOSPITAL   (Italy)

^l UNIVERSITY OF PADOVA   (Italy)

^m UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; POMALIDOMIDE; PREDNISONE;

ADULT; AGED; ANEMIA; ARTICLE; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; INFECTION; LIVER FAILURE; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGICAL COMPLICATION; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

EID: 84888218659     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-488676     Document Type: Article

References (30)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516- 2520.
3. Kumar SK, Lee JH, Lahuerta JJ, et al; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149-157.
4. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4(4):314-322.
5. Schey S, Ramasamy K. Pomalidomide therapy for myeloma. Expert Opin Investig Drugs. 2011;20(5):691-700.
6. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008-5014.
7. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970-2975.
8. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) Leukemia. 2010;24(11):1934-1939.
9. Leleu X, Attal M, Arnulf B, et al. High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02. In: 53rd ASH Annual Meeting and Exposition; December 10-13, 2011; San Diego, CA. Abstract 812.
10. Richardson PG, Siegel D, Vij R, et al. Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. In: 53rd ASH Annual Meeting and Exposition; December 10-13, 2011; San Diego, CA. Abstract 634.
11. McCarthy DA, Macey MG, Streetly M, Schey SA, Brown KA. The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64. Int Immunopharmacol. 2006;6(7):1194-1203.
12. Schey SA, Morgan GJ, Ramasamy K, et al. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol. 2010;150(3):326-333.
13. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. http://ctep. cancer.gov.
14. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
15. Palumbo A, Rajkumar SV, Dimopoulos MA, et al; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414-423.
16. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990;46(1):33-48.
17. O'Quigley J, Zohar S. Experimental designs for phase I and phase I/II dose-finding studies. Br J Cancer. 2006;94(5):609-613.
18. Zohar S, Chevret S. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Stat Med. 2001;20(19):2827- 2843.
19. Zohar S, Latouche A, Taconnet M, Chevret S. Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. Comput Methods Programs Biomed. 2003;72(2):117-125.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
21. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23(36):9219-9226.
22. Quach H, Mileshkin L, Seymour JF, et al. Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leuk Lymphoma. 2009;50(2):223-229.
23. Gertz MA, Kumar S, Lacy MQ, et al. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood. 2010;115(12):2348-2353, quiz 2560.
24. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16):3269-3276.
25. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141(1):41-51.
26. Dimopoulos MA, Lacy MQ, Moreau P, et al. Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. In: 54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA. Abstract LBA-6.
27. Reece D, Masih-Khan E, Khan A, et al. Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma. In: 51st ASH Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA. Abstract 1874.
28. Sidra G, Williams CD, Russell NH, Zaman S, Myers B, Byrne JL. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica. 2006;91(6):862-863.
29. Baz R, Shain KH, Alsina M, et al. Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort. In: 54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA. Abstract 4062.
30. Weber DM, Chen C, Niesvizky R, et al; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133-2142.